Amgen announced the release of AmgenNow, a new direct-to-patient program starting with Repatha® (evolocumab). This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial.
The program is open to all patients, including those who are uninsured, have high-deductible health plans, or prefer to pay with cash or out-of-pocket. Participants are not subject to insurer requirements such as step therapy or prior authorization. Repatha is now available to individuals on Medicare and Medicaid through this program.
Today onwards, AmgenNow will be available to all Repatha patients, including those who participate in government programs such as Medicare and Medicaid. Patients who use this program are not subject to insurer requirements for step therapy or prior authorization. The company also plans to make AmgenNow accessible via the TrumpRx website.
Executive Statement
According to Murdo Gordon, executive vice president of Global Commercial Operations at Amgen, Amgen is committed to finding new ways to help patients benefit from their medicines. Repatha has already helped more than 5 million patients, and the AmgenNow program will make it easier for uninsured patients or those who choose to pay out-of-pocket to access treatment. This will allow even more Americans at increased risk of major adverse cardiovascular events to benefit from this effective medicine.
